The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure (NCT04069715) | Clinical Trial Compass
CompletedPhase 2
The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure
95 participantsStarted 2016-07-20
Plain-language summary
In this randomized, placebo-controlled, double-blind parallel study in human participants with elevated LDL-C and elevated BP described here, the clinical benefits of Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract), a product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1 and ginsenoside Rg1, will be investigated for its efficacy on LDL-C and blood pressure.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Male and females age 18-75 years (inclusive)
. BMI 23.0 to 32.5 kg/m2
. Participants with LDL-C ≥2.6 mmol/L and \<3.8 mmol/L (≥ 100 mg/dL and \< 150 mg/dL)
. Participants with pre-hypertension (systolic blood pressure of greater than or equal to 100 and less than 140 mmHg)
. Participants agree to follow a therapeutic lifestyle changes (TLC) diet
. If female, participant is not of child bearing potential, which is defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with \> 1 year since last menstruation)
. Willing to maintain current physical activity patterns throughout the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The Difference in Serum LDL-C From Baseline to Week 12 Between Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng Extract) and Placebo After 12 Weeks of Supplementation.
Timeframe: 12 weeks
Trial details
NCT IDNCT04069715
SponsorLongStar HealthPro, Inc. DBA Farlong Pharmaceutical
. Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits
Exclusion criteria
. History of allergic reaction or hypersensitivity to any of the study supplement components
. Pregnant, breastfeeding, or planning to become pregnant during the course of the trial.
. Use of cholesterol-lowering or blood pressure lowering prescription drugs within the last 6 months prior to randomization
. LDL-C ≥ 3.37 mmol/L (130 mg/dL), if the 10-year risk of cardiovascular event is ≥ 20% as estimated by the Framingham risk score
. LDL-C \> 3.5 mmol/L (135.34 mg/dL) OR if the total cholesterol vs. HDL-C ratio is \> 5.0 OR hs-CRP \> 2 mg/L in males \> 50 years and females \> 60 years, and if the 10-year Framingham risk score is 10-19%
. Total cholesterol vs. HDL-C ratio \> 6.0, if the 10-year Framingham risk score is \< 10%
. Use of ginseng-based drinks or products
. Health supplements that affect blood pressure and cholesterol levels other than vitamins and minerals, such as plant sterols, omega-3, fish oil, soy protein, soluble oat fiber, psyllium seed husk, licorice or other blood pressure and cholesterol lowering nonprescription supplements within 1 month of enrollment and during the study